Currently, there are 125.78M common shares owned by the public and among those 116.27M shares have been available to trade.
The company’s stock has a 5-day price change of 21.85% and -35.21% over the past three months. XRX shares are trading -35.82% year to date (YTD), with the 12-month market performance down to -59.60% lower. It has a 12-month low price of $3.44 and touched a high of $14.81 over the same period. XRX has an average intraday trading volume of 4.64 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 27.53%, 5.50%, and -35.79% respectively.
Institutional ownership of Xerox Holdings Corp (NASDAQ: XRX) shares accounts for 97.21% of the company’s 125.78M shares outstanding.
It has a market capitalization of $680.47M and a beta (3y monthly) value of 1.84. The earnings-per-share (ttm) stands at -$10.55. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.52% over the week and 9.06% over the month.
Analysts forecast that Xerox Holdings Corp (XRX) will achieve an EPS of 0.09 for the current quarter, 0.34 for the next quarter and 1.45 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.07 while analysts give the company a high EPS estimate of 0.07. Comparatively, EPS for the current quarter was 0.29 a year ago. Earnings per share for the fiscal year are expected to decrease by -14.69%, and 85.70% over the next financial year.
Looking at the support for the XRX, a number of firms have released research notes about the stock. Citigroup stated their Sell rating for the stock in a research note on June 28, 2024, with the firm’s price target at $11. Credit Suisse coverage for the Xerox Holdings Corp (XRX) stock in a research note released on August 17, 2022 offered a Underperform rating with a price target of $14. Morgan Stanley was of a view on February 04, 2021 that the stock is Underweight, while Credit Suisse gave the stock Neutral rating on January 27, 2021, issuing a price target of $23- $20. Cross Research on their part issued Sell rating on January 19, 2021.
